Zobrazeno 1 - 10
of 57
pro vyhledávání: '"Tsuyoshi, Takashima"'
Autor:
Seijiro Hamada, Satoshi Kano, Junko Murai, Takayoshi Suzuki, Nayuta Tsushima, Takatsugu Mizumachi, Masanobu Suzuki, Tsuyoshi Takashima, Daiki Taniyama, Naoya Sakamoto, Yoichiro Fujioka, Yusuke Ohba, Akihiro Homma
Publikováno v:
Frontiers in Oncology, Vol 12 (2023)
Recently, Schlafen family member 11 (SLFN11) has been reported to increase the sensitivity of cancer cells to DNA-damaging agents, including platinum derivatives; thus, SLFN11 may be a predictive biomarker for platinum-based chemoradiotherapy (CRT).
Externí odkaz:
https://doaj.org/article/6736169236714c84b7fe1c69b6f463b5
Publikováno v:
Anticancer Research. 43:2501-2507
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7315088e6e3b9ba2708eecbeace16495
https://doi.org/10.21873/anticanres.16417
https://doi.org/10.21873/anticanres.16417
Autor:
Eriko Nonaka, Tsuyoshi Takashima, Keiichirou Matsumoto, Makoto Fukuda, Shuichi Rikitake, Motoaki Miyazono
Publikováno v:
Clinical Case Reports, Vol 9, Iss 5, Pp n/a-n/a (2021)
Abstract We experienced a case in which improving the renal damage caused by warfarin‐related nephropathy took a long time. It is important to follow up for a long time after the initiation of dialysis due to warfarin‐related nephropathy.
Externí odkaz:
https://doaj.org/article/082f96d8d523457e8170807e4bdac5ac
Autor:
Fumiya Moribe, Momoko Nishikori, Tsuyoshi Takashima, Daiki Taniyama, Nobuyuki Onishi, Hiroshi Arima, Hiroyuki Sasanuma, Remi Akagawa, Fathi Elloumi, Shunichi Takeda, Yves Pommier, Eiichi Morii, Akifumi Takaori-Kondo, Junko Murai
Publikováno v:
PLoS ONE, Vol 16, Iss 1, p e0237554 (2021)
BackgroundSLFN11 has recently been reported to execute cancer cells harboring replicative stress induced by DNA damaging agents. However, the roles of SLFN11 under physiological conditions remain poorly understood. Germinal center B-cells (GCBs) unde
Externí odkaz:
https://doaj.org/article/bd3783f480924af5b7bd34d5f263915e
Autor:
Kansuke Kido, Satoshi Nojima, Daisuke Motooka, Yusuke Nomura, Masaharu Kohara, Kazuaki Sato, Kenji Ohshima, Shinichiro Tahara, Masako Kurashige, Daisuke Umeda, Tsuyoshi Takashima, Hiroki Kiyokawa, Koto Ukon, Takahiro Matsui, Daisuke Okuzaki, Eiichi Morii
Publikováno v:
The Journal of Pathology. 260:56-70
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::69cd4e2db67bdd9b1a6ba8e6ab0754c0
https://doi.org/10.1002/path.6064
https://doi.org/10.1002/path.6064
Autor:
Yuki Awanami, Makoto Fukuda, Yasunori Nonaka, Tsuyoshi Takashima, Keiichiro Matsumoto, Masatora Yamasaki, Motoaki Miyazono, Yuji Ikeda
Publikováno v:
BMC Nephrology, Vol 18, Iss 1, Pp 1-4 (2017)
Abstract Background The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab is a low-density lipoprotein (LDL)-lowering drug with a new mechanism, which is currently available in Japan. Here, for the first time, we report the s
Externí odkaz:
https://doaj.org/article/4b0e28ce3a934284b4ff1d70406bb687
Autor:
Quoc Thang Pham, Daiki Taniyama, Shintaro Akabane, Tsuyoshi Takashima, Ryota Maruyama, Yohei Sekino, Kazuhiro Sentani, Wataru Yasui, Naohide Oue
Publikováno v:
Pathobiology. 90:44-55
Introduction: Tryptophan metabolism has been shown to be involved in tumor development. Two main tryptophan-degrading enzymes, tryptophan 2,3-dioxygenase (TDO2) and indoleamine 2,3-dioxygenase 1 (IDO1), may potently promote cancer cell survival and d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e68207adf1615e06c20cca8409ed8586
https://doi.org/10.1159/000523750
https://doi.org/10.1159/000523750
Autor:
Toru Sanai, Ken Okamura, Shuichi Rikitake, Tsuyoshi Takashima, Motoaki Miyazono, Yuji Ikeda, Takanari Kitazono
Publikováno v:
Cogent Medicine, Vol 4, Iss 1 (2017)
Difference in thyroid function depending on the etiology of end-stage renal disease (ESRD) was evaluated in 124 Japanese patients on haemodialysis (HD) due to either chronic glomerulonephritis (CGN, n = 82) or lifestyle related systemic disease (non-
Externí odkaz:
https://doaj.org/article/2d85ea2023ad41e8b9232a120d5ee3e1
Autor:
Daiki Taniyama, Takuya Hattori, Kenji Harada, Eiichi Morii, Shoichi Ukai, Hideki Ohdan, Ririno Honma, Atsuo T. Sasaki, Junko Murai, Tsuyoshi Takashima, Maika Yasumoto, Kazuya Kuraoka, Ryuichi Asai, Wataru Yasui, Naoya Sakamoto, Kazuaki Tanabe, Pham Quoc Thang, Ryota Maruyama
Publikováno v:
Br J Cancer
BACKGROUND: Although unresectable or recurrent gastric cancers (GC) are frequently treated with platinum-based chemotherapy, response to treatment remains unpredictable. Because Schlafen 11 (SLFN11) is recently identified as a critical determinant of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3195a3ac0bf8bef0977e4fb9d1026b33
https://doi.org/10.1038/s41416-021-01364-3
https://doi.org/10.1038/s41416-021-01364-3
Autor:
Wataru Yasui, Kazuhito Naka, Quoc Thang Pham, Ririno Honma, Yusuke Yamamoto, Ryuichi Asai, Tsuyoshi Takashima, Kenji Harada, Kazuaki Tanabe, Daiki Taniyama, Kaho Fukada, Naoya Sakamoto, Shoichi Ukai, Hideki Ohdan
Publikováno v:
Oncogene. 39:7265-7278
5-FU is one of the key drugs in the treatment of gastric cancer (GC). Much evidence has shown that cancer stem cells (CSCs) play a key role in the acquisition of drug resistance. The organoid is a novel 3D cell culture system technology that sustains
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d921532ff5cd35630328974ea405792f
https://doi.org/10.1038/s41388-020-01492-9
https://doi.org/10.1038/s41388-020-01492-9